PHIO logo

Phio Pharmaceuticals Stock Price

Symbol: NasdaqCM:PHIOMarket Cap: US$11.2mCategory: Pharmaceuticals & Biotech

PHIO Share Price Performance

US$2.37
-0.40 (-14.44%)
US$2.37
-0.40 (-14.44%)
Price US$2.37

PHIO Community Narratives

There are no narratives available yet.

PHIO Community Fair Values

    Recent PHIO News & Updates

    No updates

    Phio Pharmaceuticals Corp. Key Details

    US$0

    Revenue

    US$3.7m

    Cost of Revenue

    -US$3.7m

    Gross Profit

    US$3.1m

    Other Expenses

    -US$6.8m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -1.41
    Gross Margin
    0%
    Net Profit Margin
    0%
    Debt/Equity Ratio
    0%

    Phio Pharmaceuticals Corp. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About PHIO

    Founded
    2011
    Employees
    5
    CEO
    Robert Bitterman
    WebsiteView website
    phiopharma.com

    Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

    U.S. Market Performance

    • 7 Days: -1.2%
    • 3 Months: 13.1%
    • 1 Year: 22.8%
    • Year to Date: 7.3%
    Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading